Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

69.80 +0.87 (+1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Cor

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months?
Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,... 
Via Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
Unusual Options Activity Insight: Exact Sciences
Exact Sciences (NASDAQ:EXAS) shares experienced unusual o... 
Via Benzinga
Unusual Options Activity Insight: Exact Sciences
On Tuesday, shares of Exact Sciences (NASDAQ:EXAS) saw un... 
Via Benzinga
Expert Ratings for Exact Sciences
Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the fol... 
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
Why Exact Sciences Share Are Falling Today?
Exact Sciences Corp (NASDAQ: EXAS) has put down $190 million to buy testing laboratory PreventionGenetics, aiming to expand its diagnostics franchise into... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell
Its positioning in cancer diagnostics is good, but it faces an important headwind. 
Via The Motley Fool
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the... 
Via FinancialNewsMedia
Exact Sciences Breaks Up With Pfizer -- Time to Buy?
The end of a co-promotion deal with Pfizer could work out well for Exact Sciences. 
Via The Motley Fool
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test
Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal... 
Via Benzinga
Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought
The internet's favorite stock picker has been very busy. 
Via The Motley Fool
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021
Upgrades Benchmark upgraded the previous rating for Devon Energy Corp (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Needham boosted Paycom Software, Inc. (NYSE:PAYC) ... 
Via Benzinga
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to... 
Via Benzinga
Exact Sciences Shares Drop After Guiding Lower Screening Revenue For FY21
Exact Sciences Corp's (NASDAQ: EXAS) Q3 revenues rose 12% Y/Y to $456.4 million, beating the consensus of $430.03 million. The increase is attributable to increased... 
Via Benzinga
Exact Sciences (EXAS) Q3 2021 Earnings Call Transcript
EXAS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Why Exact Sciences' Stock Is Trading Higher Today
Exact Sciences (NASDAQ:EXAS) shares are trading higher after the company announced an expansion of its primary care sales team with the addition of former Pfizer sales... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
3 Crash-Ready Stocks to Buy in September
History says this month can be scary. These stocks can get you through it. 
Via The Motley Fool
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused... 
Via Benzinga
3 Top Healthcare Stocks to Buy for August
With excellent prospects, these three companies are built to last and today's prices are attractive. 
Via The Motley Fool
44 Stocks Moving In Thursday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia.... 
Via Benzinga
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.